Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Kasugamycin is a novel chitinase 1 inhibitor with strong antifibrotic effects on pulmonary fibrosis

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.02.25.432796Source: DataRank Database

Kasugamycin is a novel chitinase 1 inhibitor with strong antifibrotic effects on pulmonary fibrosis is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2021). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: greenTopics (45)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Chang-Min Lee ORCID,Joyce H. Lee ORCID,Mun-Ock Kim ORCID,Jin Wook Park,Suchitra Kamle ORCID

Live enrichment

PubMed:21097893 OpenAlex:https://openalex.org/W3134389970

National Institutes of Health

Grant: 5R01HL155558-02

Chitinase1 Regulation of Pulmonary Fibrosis and Therapeutic Targeting

National Institutes of Health

Grant: 5R01HL115813-02

Chitinase1 as a Biomarker and Therapeutic Target in Scleroderma Lung Disease

National Institutes of Health

Grant: 5P01HL114501-02

Distinct and Overlapping Pathways of Fibrosis and Emphysema in Cigarette Smokers

National Institutes of Health

Grant: 1P20GM103652-01A1

Sex Hormones and Pulmonary Vascular and Right Ventricular Dysfunction

greenLicense: https://www.biorxiv.org/about/FAQ#license

repositoryhttps://www.biorxiv.org/content/biorxiv/early/2021/02/26/2021.02.25.432796.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2021.02.25.432796

repositoryhttps://doi.org/10.1101/2021.02.25.432796

https://doi.org/10.1165/rcmb.2021-0156oc

Fields of Study

Studies on Chitinases and ChitosanasesInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisPeptidase Inhibition and Analysis0301 basic medicine03 medical and health sciences0303 health sciences

Keywords

Pulmonary fibrosisIn vivoFibrosisBleomycinPharmacologyLungBiologyMedicineCancer researchImmunologyPathologyInternal medicineTGF-βchitinase 1610kasugamycinPulmonary Fibrosis* / chemically inducedInbred C57BLFibroblasts / metabolismMiceLung / pathologyAminoglycosides* / therapeutic useAntifibrotic Agents* / pharmacologyTransforming Growth Factor betaAntifibrotic Agents* / therapeutic useTransforming Growth Factor beta / metabolismAnimalsHumansBleomycin / pharmacologyTGFBRAP1ChitinasesLung / drug effectsFibroblastsChitinases* / antagonists & inhibitorsMice, Inbred C57BLAminoglycosidesAminoglycosides* / pharmacologyPulmonary Fibrosis* / drug therapyAntifibrotic Agents

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being